Dare Bioscience (DARE) Interest Coverage Ratio (2016 - 2025)
Dare Bioscience's (DARE) quarterly Interest Coverage Ratio came in at 34.17 in Q1 2025, down 18.68% on a YoY basis from 42.02 in Q1 2024, and down 18.68% quarter-over-quarter from 28.8 in Q1 2024.
Powered by 
Analysis
Dare Bioscience (DARE) Interest Coverage Ratio (2016 - 2025) Analysis & Trends
Dare Bioscience (DARE) has reported Interest Coverage Ratio for 4 consecutive years, with 34.17 the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, Interest Coverage Ratio fell 18.68% year-over-year to 34.17; the trailing twelve-month figure through Mar 2025 stood at 19.3 (up 1.17% YoY), and the FY2017 full-year result was 34.65, down 131.34% from the prior year.
- Interest Coverage Ratio fell to 34.17 in Q1 2025 per DARE's latest filing, from 28.8 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 28.8 in Q1 2024 and bottomed at 34.17 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.08 |
| 10 | Dare Bioscience | 10.92 Mn | -1.70 Mn | -132,343.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -34.17 |
| Mar 31, 2024 | -28.80 |
| Mar 31, 2017 | -0.29 |
| Dec 31, 2016 | -0.41 |
| Sep 30, 2016 | -0.01 |